NASDAQ:ITCI - Intra-Cellular Therapies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.43
  • Forecasted Upside: 8.76 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.43 (1.00%)

This chart shows the closing price for ITCI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Intra-Cellular Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ITCI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITCI

Analyst Price Target is $47.43
▲ +8.76% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Intra-Cellular Therapies in the last 3 months. The average price target is $47.43, with a high forecast of $70.00 and a low forecast of $36.00. The average price target represents a 8.76% upside from the last price of $43.61.

This chart shows the closing price for ITCI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Intra-Cellular Therapies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/29/2020Cantor FitzgeraldBoost Price TargetOverweight$53.00 ➝ $54.00N/A
12/15/2020Bank of AmericaInitiated CoverageBuy$40.00High
12/10/2020The Goldman Sachs GroupInitiated CoverageBuy$38.00High
11/2/2020Royal Bank of CanadaLower Price TargetOutperform$43.00 ➝ $36.00High
11/2/2020BTIG ResearchLower Price TargetBuy$80.00 ➝ $40.00High
10/5/2020Canaccord GenuityReiterated RatingBuyHigh
9/10/2020Royal Bank of CanadaBoost Price Target$33.00 ➝ $43.00High
9/9/2020BTIG ResearchBoost Price Target$68.00 ➝ $80.00Low
9/9/2020JMP SecuritiesBoost Price TargetOutperform$47.00 ➝ $54.00N/A
8/11/2020Canaccord GenuityReiterated RatingBuy$70.00Low
3/3/2020BTIG ResearchLower Price TargetBuy$73.00 ➝ $68.00Medium
3/3/2020Canaccord GenuityReiterated RatingBuyMedium
2/19/2020Evercore ISIInitiated CoverageOutperformMedium
2/18/2020Cantor FitzgeraldReiterated RatingOverweight$43.00 ➝ $47.00High
1/31/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$19.00 ➝ $26.00Low
12/23/2019Canaccord GenuityBoost Price TargetBuy$29.00 ➝ $65.00High
12/23/2019BTIG ResearchBoost Price TargetBuy$34.00 ➝ $73.00High
9/10/2019SVB LeerinkReiterated RatingBuyLow
9/10/2019JMP SecuritiesSet Price TargetBuy$21.00N/A
9/10/2019Cantor FitzgeraldSet Price TargetBuy$27.00N/A
8/12/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$16.00 ➝ $16.00Low
8/8/2019JMP SecuritiesLower Price TargetMarket Outperform$24.00 ➝ $21.00High
8/7/2019Royal Bank of CanadaSet Price TargetBuy$26.00Low
7/8/2019CowenReiterated RatingBuy$28.00High
5/23/2019Cantor FitzgeraldReiterated RatingOverweight$26.00 ➝ $29.00Medium
5/8/2019Cantor FitzgeraldReiterated RatingBuy$26.00High
4/15/2019Cantor FitzgeraldReiterated RatingBuy$26.00Medium
12/12/2018Royal Bank of CanadaBoost Price TargetOutperform$35.00 ➝ $37.00Low
12/12/2018Canaccord GenuitySet Price TargetBuy$31.00Low
12/11/2018Cantor FitzgeraldSet Price TargetBuy$32.00High
11/13/2018SVB LeerinkInitiated CoverageOutperform$27.00Medium
11/7/2018Cantor FitzgeraldReiterated RatingBuy$32.00Low
10/23/2018Cantor FitzgeraldSet Price TargetBuy$32.00Low
10/19/2018SVB LeerinkReiterated RatingOutperformHigh
10/4/2018Cantor FitzgeraldReiterated RatingBuy$32.00High
8/23/2018Cantor FitzgeraldInitiated CoverageOverweight$32.00High
8/3/2018Royal Bank of CanadaReiterated RatingBuy$35.00High
8/2/2018Cantor FitzgeraldReiterated RatingBuy$28.00High
8/2/2018Canaccord GenuitySet Price TargetBuy$31.00Low
7/23/2018Cantor FitzgeraldReiterated RatingBuy$28.00Low
6/6/2018Canaccord GenuitySet Price TargetBuy$31.00High
4/3/2018SVB LeerinkSet Price TargetBuy$25.00High
4/2/2018Canaccord GenuitySet Price TargetBuy$31.00Low
3/13/2018Canaccord GenuitySet Price TargetBuy$31.00Medium
3/4/2018SVB LeerinkReiterated RatingOutperformLow
3/2/2018SunTrust BanksReiterated RatingBuy$28.00Low
3/2/2018CowenReiterated RatingBuy$28.00High
3/1/2018Cantor FitzgeraldReiterated RatingBuy$28.00High
2/26/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$25.00High
2/8/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$33.00Medium
12/15/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$31.00High
11/8/2017SunTrust BanksUpgradeHold ➝ BuyN/A
9/8/2017BTIG ResearchReiterated RatingBuy$36.00Medium
9/8/2017SunTrust BanksReiterated RatingHold$16.00 ➝ $22.00Low
9/8/2017CowenReiterated RatingOutperform$20.00 ➝ $27.00Medium
9/7/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$14.00 ➝ $33.00High
8/24/2017Piper Jaffray CompaniesSet Price TargetHold$14.00Medium
8/24/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$24.00High
8/23/2017CowenReiterated RatingBuy$20.00High
8/23/2017SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
8/15/2017SVB LeerinkReiterated RatingMarket Perform$12.00Low
8/10/2017Piper Jaffray CompaniesSet Price TargetHold$10.00High
8/9/2017Cantor FitzgeraldReiterated RatingBuyHigh
5/11/2017Cantor FitzgeraldSet Price TargetBuy$29.00Low
5/2/2017Cantor FitzgeraldLower Price TargetOverweight$32.00 ➝ $29.00Medium
5/2/2017LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
5/2/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$29.00 ➝ $10.00High
5/1/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$22.00 ➝ $10.00High
3/20/2017SVB LeerinkReiterated RatingOutperformLow
3/2/2017Cantor FitzgeraldReiterated RatingBuy$32.00N/A
3/1/2017CowenReiterated RatingBuyN/A
2/23/2017Piper Jaffray CompaniesReiterated RatingOverweight$22.00N/A
12/22/2016BTIG ResearchInitiated CoverageBuy$44.00N/A
12/16/2016Cantor FitzgeraldInitiated CoverageOverweight$32.00N/A
11/9/2016Piper Jaffray CompaniesReiterated RatingOverweight$22.00N/A
11/1/2016Piper Jaffray CompaniesReiterated RatingOverweight$22.00N/A
10/10/2016Piper Jaffray CompaniesSet Price TargetBuy$22.00N/A
9/30/2016Royal Bank of CanadaReiterated RatingOutperform$74.00 ➝ $49.00N/A
9/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$57.00 ➝ $22.00N/A
9/30/2016SVB LeerinkReiterated RatingOutperform$95.00 ➝ $29.00N/A
9/29/2016JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
9/29/2016Royal Bank of CanadaLower Price TargetOutperform$74.00 ➝ $49.00N/A
9/29/2016SunTrust BanksDowngradeBuy ➝ Neutral$60.00 ➝ $15.00N/A
9/13/2016Piper Jaffray CompaniesReiterated RatingOverweight$57.00N/A
8/11/2016SVB LeerinkReiterated RatingBuy$95.00N/A
8/5/2016CowenReiterated RatingBuy$75.00N/A
6/30/2016SVB LeerinkReiterated RatingBuyN/A
6/29/2016CowenReiterated RatingBuyN/A
6/22/2016SVB LeerinkReiterated RatingBuyN/A
6/22/2016Piper Jaffray CompaniesReiterated RatingOverweight$57.00N/A
(Data available from 6/21/2016 forward)
Intra-Cellular Therapies logo
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also developing lumateperone, which is in Phase 3 clinical trials for the treatment of bipolar depression, as well as to treat autism spectrum disorder, and sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for the treatment of Parkinson's disease and heart failure; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $43.61
Low: $43.03
High: $43.83

50 Day Range

MA: $36.77
Low: $29.30
High: $43.33

52 Week Range

Now: $43.61
Low: $17.26
High: $43.82


9,973 shs

Average Volume

561,131 shs

Market Capitalization

$3.54 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Intra-Cellular Therapies?

The following Wall Street research analysts have issued stock ratings on Intra-Cellular Therapies in the last twelve months: Bank of America Co., BTIG Research, Canaccord Genuity, Cantor Fitzgerald, JMP Securities, Royal Bank of Canada, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for ITCI.

What is the current price target for Intra-Cellular Therapies?

7 Wall Street analysts have set twelve-month price targets for Intra-Cellular Therapies in the last year. Their average twelve-month price target is $47.43, suggesting a possible upside of 8.9%. Canaccord Genuity has the highest price target set, predicting ITCI will reach $70.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $36.00 for Intra-Cellular Therapies in the next year.
View the latest price targets for ITCI.

What is the current consensus analyst rating for Intra-Cellular Therapies?

Intra-Cellular Therapies currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ITCI will outperform the market and that investors should add to their positions of Intra-Cellular Therapies.
View the latest ratings for ITCI.

What other companies compete with Intra-Cellular Therapies?

How do I contact Intra-Cellular Therapies' investor relations team?

Intra-Cellular Therapies' physical mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company's listed phone number is 646-440-9333 and its investor relations email address is [email protected] The official website for Intra-Cellular Therapies is